Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone for Leptomeningeal TTR Amyloidosis
NCT03591757Phase 1Completed
- Sponsor
- Boston University
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolcapone in leptomeningeal transthyretin amyloidosis, sponsored by Boston University. Primary endpoints: Change in plasma TTR stabilization at Day 28 and Change in CSF TTR stabilization at Day 28. Started Oct 2018; status: completed.
02
Drugs
tolcapone
03
Conditions
leptomeningeal transthyretin amyloidosis
Beyond the preview
Go deeper on NCT03591757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591757.